<DOC>
	<DOCNO>NCT02392468</DOCNO>
	<brief_summary>Single site , parallel-group , double-blind trial low high dose BI 409306 evaluate ocular systemic safety pharmacokinetics 14 day treatment period patient schizophrenia , Alzheimer 's disease , age comparable healthy volunteer .</brief_summary>
	<brief_title>Study Systemic Ocular Safety Pharmacokinetics BI 409306 Patients With Schizophrenia , Alzheimer 's Disease , Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Inclusion criterion : Schizophrenia group : Patients establish diagnosis schizophrenia ( per Diagnostic Statistic Manual Mental Disorder , version V ) follow clinical feature : Clinically stable residual ( nonacute ) phase illness least 8 week prior randomisation Current antipsychotic concomitant psychotropic medication must meet criterion : Maintained current atypical ( second generation ) antipsychotic medication ( approve dosage form ) Clozapine current dose least 8 week prior randomisation , and/or Maintained current typical ( first generation ) antipsychotic medication current dose least 6 month , optionally combine anticholinergic treat stable dose least 6 month prior randomisation , and/or Maintained current concomitant psychotropic medication anticholinergic , antiepileptic lithium , current dose least 8 week prior randomisation . Antiepileptics lithium allow initiate least 6 month prior randomisation . Have moderate severity rating hallucination delusion ( Positive Negative Syndrome Scale ( PANSS ) , positive syndrome Hallucinatory Behavior item score &lt; = 4 Delusions item score &lt; = 4 ) Have moderate severity rating positive formal think disorder ( PANSS , positive syndrome Conceptual Disorganization item score &lt; = 4 ) Have minimal level extrapyramidal symptom ( SimpsonAngus Scale total score &lt; 6 ) depressive symptom ( PANSS , general psychopathology syndrome Depression item score &lt; = 4 ) Male female patient age 18 55 year . Alzheimer 's Disease group : Patients diagnosis mild Alzheimer 's Dementia base DSMV accordance recommendation National Institute AgingAlzheimer 's Association workgroups diagnostic guideline Alzheimer 's disease . MiniMental State Examination ( MMSE ) score 1826 . Male female patient age 55 85 year , take acetyl cholinesterase inhibitor ( donepezil , galantamine , rivastigmine ) and/or memantine least 3 month stable dose acetyl cholinesterase inhibitor ( donepezil , galantamine , rivastigmine ) and/or memantine least 3 month randomization . Availability preexist cranial computer tomography ( CCT ) magnetic resonance imaging ( MRI ) scan brain ( initiation radiological imaging require ) old one year prior screening ; available , CCT must perform screening . Results radiological brain imaging must compatible Diagnosis Alzheimer 's Disease exclusion relevant sign indicative potential vascular dementia ( see also exclusion criterion ) . If need , caregiver may present site activity . Agecomparable male female healthy volunteer age 18 85 year : After 10 patient schizophrenia ( describe ) enter study , median age group compute . Five healthy volunteer median age great 18 year old five healthy volunteer median less 55 enter study . Similarly , 10 patient AD enter , median age compute . Five healthy volunteer median age great 55 year old five healthy volunteer median less 85 enter study . Subjects must exhibit reliability physiologic capability comply protocol procedure . Signed date write informed consent date Visit 1 accordance Good Clinical Practice local legislation . If patient need legal representative , legal representative must give write informed consent well . Exclusion criterion : Presence active ocular condition without visual impairment due cause ( e.g . cataract , chorioretinal macular lesion , amblyopia , active diabetic retinopathy , uncontrolled glaucoma , active inflammation infection , etc . ) one eye eye screen phase . Planned ocular treatment ( e.g . intravitreal antivascular growth factor , corticosteroid ) surgery study period . Current plan use ocular systemic corticosteroid . Current plan use medication know toxic retina , lens , optic nerve Subjects treat two antipsychotic medication ( include two dosage form ) . Dementia Alzheimers Disease patient , secondary disorder ( base clinical data and/or current laboratory finding and/or preexist cranial MRI CCT ) . Neurological disease ( Dementia Alzheimer Type : Lewy body dementia primary diagnosis , Huntington 's disease , Parkinson 's Disease encephalitis , epilepsy , vascular multiinfarct dementia , stroke , congenital mental deficiency , multiple sclerosis ) , mental retardation . Subjects participate study innovative causal intervention AD . Subjects need take longacting hypnotic anxiolytic ( i.e . Diazepam ) . For AD patient , follow drug prohibit 3 month prior randomization duration trial : tricyclic antidepressant , antidepressant monoamine oxidase inhibitor , neuroleptic moderate great anticholinergic potency ( e.g. , chlorpromazine , fluphenazine , loxapine , perphenazine , thioridazine ) , anticholinergic medication . Intake St. John 's wort , Carbamazepine extract Ginko relevant CYP2C19 inducer . Substantial concomitant cerebrovascular disease ( defined history stroke/intracranial haemorrhagia temporally related onset worsen cognitive impairment ) . Any suicidal ideation type 4 5 Columbia Suicidal Severity Rating Scale ( CSSRS ) past 3 month . Any suicidal behavior past 2 year ( i.e . actual attempt , interrupt attempt , abort attempt , preparatory act behavior ) . History diagnosis symptomatic unstable/uncontrolled gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological , haematological hormonal disorder . For female subject : Premenopausal woman ( last menstruation &lt; =1 year prior informed consent ) : nursing pregnant childbearing potential practicing acceptable method birth control For male subject : Men able father child , unwilling abstinent use adequate contraception . Known history , new diagnosis HIV infection . Significant renal disease ( CLCR &lt; 30 mL/min ) . Bodyweight &lt; 50 kg . Indication liver disease . History neurologic ( e.g . stroke , seizure without clear resolve etiology , concussion accompany loss consciousness ) psychiatric condition . History malignancy within last 5 year , except basal cell carcinoma . Planned elective surgery require general anaesthesia , hospitalisation study period . Significant history drug dependence Clinically significant uncompensated hearing loss . Use hear aid allow . Further exclusion criterion apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>